Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Dr. Bernstein has served as President, Head of Research and Development, and Chief Medical Officer since October 2022, previously holding senior roles at BioMarin Pharmaceutical, Vertex, and Merck. He holds an A.B. from Harvard College and an M.Phil., Ph.D. in Human Genetics and M.D. from the Icahn School of Medicine at Mount Sinai.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Aclaris Therapeutics, Inc.

2024-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Aclaris Therapeutics, Inc.

Open Aclaris Therapeutics, Inc. profile →

Director at Aclaris Therapeutics, Inc.

2024-01-01 → End not stated

current · source reported

Observed: 2026-09-26

Aclaris Therapeuti…Aclaris Therapeutics, Inc.Harold S. Bernstei…

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingMAZE DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open sourceSource 2 · Sec FilingACRS DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open sourceSource 3 · Sec FilingNUVL 10-K executive officersSupports Executive company, Executive title.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:hugh-davis-ph-d
Record version
public-0

Published evidence records

7 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. MAZE DEF 14A executive officers

    sec filing · Source published: Apr 28, 2026 · Retrieved: May 4, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 4, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 4, 2026
    • Executive company: Executive at Maze Therapeutics, Inc. · Claim reviewed: May 4, 2026
    • Executive title: Executive title: President, Research and Development and Chief Medical Officer · Claim reviewed: May 4, 2026
    • Other Company Role: Harold S. Bernstein, M.D., Ph.D. is also linked to Icahn School of Medicine at Mount Sinai as Adjunct Professor of Pediatrics (Cardiology). · Claim reviewed: May 4, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 4, 2026

  2. ACRS DEF 14A director slate

    sec filing · Source published: Apr 23, 2026 · Retrieved: Apr 24, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 4, 2026
    • Board role: Board role: Director · Claim reviewed: Apr 24, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: Apr 24, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 4, 2026
    • Executive company: Executive at Aclaris Therapeutics, Inc. · Claim reviewed: Apr 24, 2026
    • Executive title: Executive title: President and Chief Operating Officer · Claim reviewed: Apr 24, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 4, 2026

  3. Aclaris Therapeutics, Inc. director board source

    sec filing · Source published: Apr 23, 2026 · Retrieved: May 3, 2026

    Supports 2 claims
    • Board independence: Not independent (executive director) · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Aclaris Therapeutics, Inc. · Claim reviewed: May 3, 2026

  4. Open source

    sec proxy · Source published: Apr 23, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Aclaris Therapeutics, Inc. · Claim reviewed: May 4, 2026

  5. NUVL 10-K executive officers

    sec filing · Source published: Feb 26, 2026 · Retrieved: May 1, 2026

    Supports 2 claims
    • Executive company: Executive at Nuvalent Inc · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Chief Scientific Officer · Claim reviewed: May 3, 2026

  6. NUVL executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise: not identified in the cited filing · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance: not identified in the cited filing · Claim reviewed: May 3, 2026
    • Executive company: Executive at Nuvalent Inc · Claim reviewed: May 3, 2026
    • Executive function: Other Executive (OTHER_EXECUTIVE) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Chief Scientific Officer · Claim reviewed: May 3, 2026

  7. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Aclaris Therapeutics, Inc. · Claim reviewed: May 3, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

AI expertise · Source reportedAI expertise: not identified in the cited filing1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

AI governance relevance · Source reportedAI governance relevance: not identified in the cited filing1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board independence · Source reportedNot independent (executive director)1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · CorroboratedServes on the board of Aclaris Therapeutics, Inc.Supported by 3 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
Apr 24, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
88%
Last reviewed
Apr 24, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Executive company · Source reportedExecutive at Aclaris Therapeutics, Inc.1 source
Verification
Source reported
Confidence
85%
Last reviewed
Apr 24, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

Executive company · Source reportedExecutive at Maze Therapeutics, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Executive company · CorroboratedExecutive at Nuvalent IncSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive function · Source reportedOther Executive (OTHER_EXECUTIVE)1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive title · CorroboratedExecutive title: Chief Scientific OfficerSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive title · Source reportedExecutive title: President and Chief Operating Officer1 source
Verification
Source reported
Confidence
85%
Last reviewed
Apr 24, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

Executive title · Source reportedExecutive title: President, Research and Development and Chief Medical Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Other Company Role · Source reportedHarold S. Bernstein, M.D., Ph.D. is also linked to Icahn School of Medicine at Mount Sinai as Adjunct Professor of Pediatrics (Cardiology).1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

View all sources7 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Director since · Board independence

  4. https://www.sec.gov/Archives/edgar/data/1557746/000110465926047262/acrs-20260604xdef14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at Aclaris Therapeutics, Inc. (NASDAQ: ACRS)

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 1, 2026

    Supports: Executive company · Executive title

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: AI expertise · AI governance relevance · Executive company · Executive function · Executive title

  7. https://www.sec.gov/Archives/edgar/data/1557746/000110465926047262/acrs-20260604xdef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership